Zimmer Biomet Holdings, Inc., a global medical technology leader, announced its RibFix Advantage Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system.
The RibFix Advantage Fixation System is intended for the thoracoscopic fixation, stabilization and fusion of rib fractures, allowing for a minimally invasive approach compared with traditional open reduction internal fixation, with the potential for less soft tissue disruption. The RibFix Advantage Bridge adapts to the anatomy of the rib during tightening and auto-contours to reduce the fracture. The system and surgical technique offer an innovative advancement in rib fracture management.
""Following the success of RibFix Advantage Fixation System in the United States and other markets, we are excited to introduce it in CE Mark markets and support our customers with solutions that meet their evolving surgical needs,"" said Wilfred van Zuilen, Zimmer Biomet Group president, EMEA. ""We remain dedicated to advancing MedTech and delivering high-quality solutions for healthcare professionals and their patients worldwide.""
With the CE Mark, Zimmer Biomet will make the RibFix Advantage Fixation System available in the European Economic Area (EEA) and other markets that recognize the CE Mark.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.